Multiple endocrine neoplasia type 1 screening: Difference between revisions
Line 7: | Line 7: | ||
==Screening== | ==Screening== | ||
Screening and surveillance for multiple endocrine neoplasia type 1 may employ a combination of biochemical tests and imaging. Available recommendations are summarized in the following table. <ref name="pmid1677362">{{cite journal| author=Skogseid B, Eriksson B, Lundqvist G, Lörelius LE, Rastad J, Wide L et al.| title=Multiple endocrine neoplasia type 1: a 10-year prospective screening study in four kindreds. | journal=J Clin Endocrinol Metab | year= 1991 | volume= 73 | issue= 2 | pages= 281-7 | pmid=1677362 | doi=10.1210/jcem-73-2-281 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1677362 }} </ref> <ref name="pmid9024241">{{cite journal| author=Stock JL, Warth MR, Teh BT, Coderre JA, Overdorf JH, Baumann G et al.| title=A kindred with a variant of multiple endocrine neoplasia type 1 demonstrating frequent expression of pituitary tumors but not linked to the multiple endocrine neoplasia type 1 locus at chromosome region 11q13. | journal=J Clin Endocrinol Metab | year= 1997 | volume= 82 | issue= 2 | pages= 486-92 | pmid=9024241 | doi=10.1210/jcem.82.2.3730 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9024241 }} </ref> <ref name="pmid9920064">{{cite journal| author=Baudin E, Bidart JM, Rougier P, Lazar V, Ruffié P, Ropers J et al.| title=Screening for multiple endocrine neoplasia type 1 and hormonal production in apparently sporadic neuroendocrine tumors. | journal=J Clin Endocrinol Metab | year= 1999 | volume= 84 | issue= 1 | pages= 69-75 | pmid=9920064 | doi=10.1210/jcem.84.1.5445 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9920064 }} </ref> <ref name="pmid19622622">{{cite journal| author=Newey PJ, Jeyabalan J, Walls GV, Christie PT, Gleeson FV, Gould S et al.| title=Asymptomatic children with multiple endocrine neoplasia type 1 mutations may harbor nonfunctioning pancreatic neuroendocrine tumors. | journal=J Clin Endocrinol Metab | year= 2009 | volume= 94 | issue= 10 | pages= 3640-6 | pmid=19622622 | doi=10.1210/jc.2009-0564 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19622622 }} </ref> <ref name="pmid20948872">{{cite journal |vauthors=Falchetti A |title=Genetic screening for multiple endocrine neoplasia syndrome type 1 (MEN-1): when and how |journal=F1000 Med Rep |volume=2 |issue= |pages= |year=2010 |pmid=20948872 |pmc=2948394 |doi=10.3410/M2-14 |url=}}</ref> | Screening and surveillance for multiple endocrine neoplasia type 1 may employ a combination of biochemical tests and imaging. Available recommendations are summarized in the following table. <ref name="pmid1677362">{{cite journal| author=Skogseid B, Eriksson B, Lundqvist G, Lörelius LE, Rastad J, Wide L et al.| title=Multiple endocrine neoplasia type 1: a 10-year prospective screening study in four kindreds. | journal=J Clin Endocrinol Metab | year= 1991 | volume= 73 | issue= 2 | pages= 281-7 | pmid=1677362 | doi=10.1210/jcem-73-2-281 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1677362 }} </ref><ref name="pmid9024241">{{cite journal| author=Stock JL, Warth MR, Teh BT, Coderre JA, Overdorf JH, Baumann G et al.| title=A kindred with a variant of multiple endocrine neoplasia type 1 demonstrating frequent expression of pituitary tumors but not linked to the multiple endocrine neoplasia type 1 locus at chromosome region 11q13. | journal=J Clin Endocrinol Metab | year= 1997 | volume= 82 | issue= 2 | pages= 486-92 | pmid=9024241 | doi=10.1210/jcem.82.2.3730 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9024241 }} </ref><ref name="pmid9920064">{{cite journal| author=Baudin E, Bidart JM, Rougier P, Lazar V, Ruffié P, Ropers J et al.| title=Screening for multiple endocrine neoplasia type 1 and hormonal production in apparently sporadic neuroendocrine tumors. | journal=J Clin Endocrinol Metab | year= 1999 | volume= 84 | issue= 1 | pages= 69-75 | pmid=9920064 | doi=10.1210/jcem.84.1.5445 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9920064 }} </ref><ref name="pmid19622622">{{cite journal| author=Newey PJ, Jeyabalan J, Walls GV, Christie PT, Gleeson FV, Gould S et al.| title=Asymptomatic children with multiple endocrine neoplasia type 1 mutations may harbor nonfunctioning pancreatic neuroendocrine tumors. | journal=J Clin Endocrinol Metab | year= 2009 | volume= 94 | issue= 10 | pages= 3640-6 | pmid=19622622 | doi=10.1210/jc.2009-0564 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19622622 }} </ref><ref name="pmid20948872">{{cite journal |vauthors=Falchetti A |title=Genetic screening for multiple endocrine neoplasia syndrome type 1 (MEN-1): when and how |journal=F1000 Med Rep |volume=2 |issue= |pages= |year=2010 |pmid=20948872 |pmc=2948394 |doi=10.3410/M2-14 |url=}}</ref> | ||
{| style="border: 0px; font-size: 90%; margin: 3px; width: 700px;" align="center" | {| style="border: 0px; font-size: 90%; margin: 3px; width: 700px;" align="center" |
Revision as of 14:15, 2 November 2017
Multiple endocrine neoplasia type 1 Microchapters |
Differentiating Multiple endocrine neoplasia type 1 from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Multiple endocrine neoplasia type 1 screening On the Web |
American Roentgen Ray Society Images of Multiple endocrine neoplasia type 1 screening |
Directions to Hospitals Treating Multiple endocrine neoplasia type 1 |
Risk calculators and risk factors for Multiple endocrine neoplasia type 1 screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Overview
According to the National Caner Institute, screening for multiple endocrine neoplasia type 1 by imaging studies such as brain MRI, abdominal CT and abdominal MRI is recommended every 3-5 year among patients with pituitary tumors and pancreatic neuroendocrine tumors respectively. Biochemical tests such as serum prolactin, insulin-like growth factor 1, fasting total serum calcium, ionized calcium, parathyroid hormone, fasting serum gastrin, chromogranin A, pancreatic polypeptide, glucagon and vaso-intestinal polypeptide are recommended every year among patients with pituitary tumors, pancreatic neuroendocrine tumors and primary hyperparathyroidism.
Screening
Screening and surveillance for multiple endocrine neoplasia type 1 may employ a combination of biochemical tests and imaging. Available recommendations are summarized in the following table. [1][2][3][4][5]
Biochemical Test or Procedure | Condition Screened For | Age Screening Initiated (y) | Frequency |
---|---|---|---|
Serum prolactin and/or insulin-like growth factor 1 | Pituitary tumors | 5 | Every 1 year |
Fasting total serum calcium and/or ionized calcium and parathyroid hormone | Parathyroidtumors and primary hyperparathyroidism | 8 | Every 1 year |
Fasting serum gastrin | Duodenopancreatic gastrinoma | 20 | Every 1 year |
Chromogranin A, pancreatic polypeptide, glucagon, and vasointestinal polypeptide | Pancreatic neuroendocrine tumors | <10years | Every 1 year |
Fasting glucose and insulin | Insulinoma | 5 | Every 1 year |
Brain MRI | Pituitary tumors | 5 | Every 3–5 years based on biochemical results |
Abdominal CT or MRI | Pancreatic neuroendocrine tumors | 20 | Every 3–5 years based on biochemical results |
Abdominal CT, MRI, or endoscopic US | Pancreatic neuroendocrine tumors | <10 | Every 1 year |
References
- ↑ Skogseid B, Eriksson B, Lundqvist G, Lörelius LE, Rastad J, Wide L; et al. (1991). "Multiple endocrine neoplasia type 1: a 10-year prospective screening study in four kindreds". J Clin Endocrinol Metab. 73 (2): 281–7. doi:10.1210/jcem-73-2-281. PMID 1677362.
- ↑ Stock JL, Warth MR, Teh BT, Coderre JA, Overdorf JH, Baumann G; et al. (1997). "A kindred with a variant of multiple endocrine neoplasia type 1 demonstrating frequent expression of pituitary tumors but not linked to the multiple endocrine neoplasia type 1 locus at chromosome region 11q13". J Clin Endocrinol Metab. 82 (2): 486–92. doi:10.1210/jcem.82.2.3730. PMID 9024241.
- ↑ Baudin E, Bidart JM, Rougier P, Lazar V, Ruffié P, Ropers J; et al. (1999). "Screening for multiple endocrine neoplasia type 1 and hormonal production in apparently sporadic neuroendocrine tumors". J Clin Endocrinol Metab. 84 (1): 69–75. doi:10.1210/jcem.84.1.5445. PMID 9920064.
- ↑ Newey PJ, Jeyabalan J, Walls GV, Christie PT, Gleeson FV, Gould S; et al. (2009). "Asymptomatic children with multiple endocrine neoplasia type 1 mutations may harbor nonfunctioning pancreatic neuroendocrine tumors". J Clin Endocrinol Metab. 94 (10): 3640–6. doi:10.1210/jc.2009-0564. PMID 19622622.
- ↑ Falchetti A (2010). "Genetic screening for multiple endocrine neoplasia syndrome type 1 (MEN-1): when and how". F1000 Med Rep. 2. doi:10.3410/M2-14. PMC 2948394. PMID 20948872.